New ultrasound could predict chemo success in weeks, not months

NCT ID NCT07581730

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a special ultrasound technique, called contrast-enhanced subharmonic ultrasound, can predict if chemotherapy is working for stomach cancer that has spread to the liver. Currently, doctors wait about 2 months for CT or MRI scans to see tumor shrinkage. This ultrasound looks at blood flow inside liver tumors before and after 1-2 chemo cycles. The goal is to see if early changes in blood flow can predict later treatment success. The study will enroll 107 adults with newly diagnosed liver metastases who have not yet started treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

contrast-enhanced subharmonic ultrasound

What this could lead to

If successful, this could allow doctors to quickly tell if chemotherapy is working for gastric cancer that has spread to the liver, enabling faster treatment adjustments.

What could go wrong

This is an early-stage study with only 107 participants, and the ultrasound technique may not reliably predict treatment response in all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER (GC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric cancer gastric neoplasm liver and intrahepatic bile duct neoplasm Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••